These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 18005387)

  • 1. Three cases of Pneumocystis jirovecii pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma.
    Venhuizen AC; Hustinx WN; van Houte AJ; Veth G; van der Griend R
    Eur J Haematol; 2008 Mar; 80(3):275-6. PubMed ID: 18005387
    [No Abstract]   [Full Text] [Related]  

  • 2. The incidence of Pneumocystis jirovecii pneumonia is not higher in patients receiving dose-dense therapy with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine, and prednisolone and adequate Pneumocystis jirovecii pneumonia prophylaxis.
    Isidori A; Merli F; Angrilli F; Ferrara F; Alesiani F; Visani G
    Leuk Lymphoma; 2011 Jan; 52(1):148-9. PubMed ID: 21067442
    [No Abstract]   [Full Text] [Related]  

  • 3. Two cases of Pneumocystis jiroveci pneumonia with non-Hodgkin's lymphoma after CHOP-based chemotherapy containing rituximab.
    Kurokawa T; Kaya H; Yoshida T
    J Clin Exp Hematop; 2010; 50(2):159-62. PubMed ID: 21123974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The increased risk for pneumocystis pneumonia in patients receiving rituximab-CHOP-14 can be prevented by the administration of trimethoprim/sulfamethoxazole: a single-center experience.
    Hardak E; Oren I; Dann EJ; Yigla M; Faibish T; Rowe JM; Avivi I
    Acta Haematol; 2012; 127(2):110-4. PubMed ID: 22178955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Rash, fever, eosinophilia and elevated liver enzymes. DRESS syndrome (drug reaction or rash with eosinophilia and systemic symptoms)].
    Derungs A; Rätz Bravo AE; Kummer O
    Praxis (Bern 1994); 2010 Jun; 99(13):767-77; quiz 776. PubMed ID: 20571998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen.
    Kolstad A; Holte H; Fosså A; Lauritzsen GF; Gaustad P; Torfoss D
    Haematologica; 2007 Jan; 92(1):139-40. PubMed ID: 17229653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A resurgence of Pneumocystis in aggressive lymphoma treated with R-CHOP-14: the price of a dose-dense regimen?
    Tadmor T; McLaughlin P; Polliack A
    Leuk Lymphoma; 2010 May; 51(5):737-8. PubMed ID: 20367567
    [No Abstract]   [Full Text] [Related]  

  • 8. Low incidence of pneumocystis pneumonia utilizing PCR-based diagnosis in patients with B-cell lymphoma receiving rituximab-containing combination chemotherapy.
    Barreto JN; Ice LL; Thompson CA; Tosh PK; Osmon DR; Dierkhising RA; Plevak MF; Limper AH
    Am J Hematol; 2016 Nov; 91(11):1113-1117. PubMed ID: 27472910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone.
    Kamel S; O'Connor S; Lee N; Filshie R; Nandurkar H; Tam CS
    Leuk Lymphoma; 2010 May; 51(5):797-801. PubMed ID: 20367135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab.
    Lim KH; Yoon HI; Kang YA; Lee KW; Kim JH; Bang SM; Lee JH; Lee CT; Lee JS
    Korean J Intern Med; 2010 Mar; 25(1):86-92. PubMed ID: 20195409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy: case report and review of the literature.
    Yokoyama H; Watanabe T; Maruyama D; Kim SW; Kobayashi Y; Tobinai K
    Int J Hematol; 2008 Nov; 88(4):443-447. PubMed ID: 18855101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) plus rituximab is effective and well tolerated in poor performance status elderly patients with non-Hodgkin's lymphoma.
    Visani G; Guiducci B; D'Adamo F; Mele A; Nicolini G; Leopardi G; Sparaventi G; Barulli S; Malerba L; Isidori A; Malagola M; Piccaluga PP
    Leuk Lymphoma; 2005 Mar; 46(3):477-9. PubMed ID: 15621843
    [No Abstract]   [Full Text] [Related]  

  • 13. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
    Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
    Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas.
    Voulgarelis M; Giannouli S; Anagnostou D; Tzioufas AG
    Rheumatology (Oxford); 2004 Aug; 43(8):1050-3. PubMed ID: 15187246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014.
    Persky DO; Unger JM; Spier CM; Stea B; LeBlanc M; McCarty MJ; Rimsza LM; Fisher RI; Miller TP;
    J Clin Oncol; 2008 May; 26(14):2258-63. PubMed ID: 18413640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma in the U.K.
    Sweetenham J; Hieke K; Kerrigan M; Howard P; Smartt PF; McIntyre AM; Townshend S
    Br J Haematol; 1999 Jul; 106(1):47-54. PubMed ID: 10444162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma.
    Katsuya H; Suzumiya J; Sasaki H; Ishitsuka K; Shibata T; Takamatsu Y; Tamura K
    Leuk Lymphoma; 2009 Nov; 50(11):1818-23. PubMed ID: 19863173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Large gastrosplenic fistula after effective treatment of abdominal diffuse large-B-cell lymphoma.
    Palmowski M; Zechmann C; Satzl S; Bartling S; Hallscheidt P
    Ann Hematol; 2008 Apr; 87(4):337-8. PubMed ID: 17929016
    [No Abstract]   [Full Text] [Related]  

  • 19. Dose-dense CHOP plus rituximab (R-CHOP14) for the treatment of elderly patients with high-risk diffuse large B cell lymphoma: a pilot study.
    Rigacci L; Nassi L; Alterini R; Carrai V; Longo G; Bernardi F; Martini V; Bosi A
    Acta Haematol; 2006; 115(1-2):22-7. PubMed ID: 16424645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Point prevalence of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma according to the number of cycles of R-CHOP chemotherapy.
    Kim T; Choi SH; Kim SH; Jeong JY; Woo JH; Kim YS; Sung H; Kim MN; Yoon DH; Suh C; Lee SO
    Ann Hematol; 2013 Jan; 92(2):231-8. PubMed ID: 23053189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.